ISPOR 2021 runs between May 17-20 with the theme of HEOR: Evolving for Tomorrow's Challenges. During the conference, PDCI Market Access will be presenting a poster titled: Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada on May 18th 2021 from 11:30:00 AM ...
INESSS has announced the implementation of a waiting list for requests for scientific evaluation received by INESSS as of November 16, 2020. PDCI has outlined below the key highlights from the most recent newsletter. The Institut national d’excellence en santé et en services sociaux (INESSS) has reported a ...
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website. CADTH has three new consultations ...
INESSS has launched a modernized website that is more user-friendly and provides greater transparency. Some of the highlighted new features includes: Enhanced search engine that allows broader searches throughout the full website and that offers additional Advance Search filters. New Social Services, Drugs and Health Services sections which provide new ...
Did you or your organization submit written comments to the recent national pharmacare consultation? If so, PDCI has volunteered to accumulate & share submissions from all stakeholders on a centrally located webpage available here. If you would like your voice added to this important policy discussion, please send ...
***Participation Requested*** Sharing Responses to the National Pharmacare Public Consultation Announced in the 2018 federal budget and chaired by former Ontario Health Minister Eric Hoskins, the Advisory Council on the Implementation of National Pharmacare is currently engaging in a national dialogue on how the federal government could implement ...
Health Canada, CADTH, and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) have officially launched efforts to align regulatory and health technology assessment (HTA) drug reviews for eligible submissions, effective immediately. Background The new process stems from Health Canada and HTAs recognizing the need for greater coordination of the ...
On April 27, 2018, Québec’s Institut national d’excellence en santé et en services sociaux (INESSS) released a notice to manufacturers advising that their submission guide document, submission checklists and various forms and letter templates have been updated effective immediately. For more information, please consult the following link or the ...